15-Year gene therapy Follow-Up for rare Deaf-Blindness condition
NCT ID NCT02065011
Summary
This study follows 9 patients for up to 15 years to monitor the long-term safety of an experimental gene therapy called SAR421869 for Usher syndrome type 1B. All participants previously received the gene therapy injection in one eye during an earlier trial. Researchers will track side effects and check whether the treatment continues to slow vision loss compared to the untreated eye.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for USHER'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 250001
Paris, 75012, France
-
Oregon Health and Science University Site Number : 840001
Portland, Oregon, 97239-3098, United States
Conditions
Explore the condition pages connected to this study.